Holen Sie sich die Stockscreener-App
7.94
0.00%
0.02
Handel nachbörslich:
7.94
Schlusskurs vom Vortag:
$7.92
Offen:
$7.84
24-Stunden-Volumen:
610.06K
Relative Volume:
1.41
Marktkapitalisierung:
$427.54M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-6.155
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
-1.61%
1M Leistung:
-0.88%
6M Leistung:
+0.89%
1J Leistung:
+26.11%
1-Tages-Spanne:
$7.62
$8.29
1-Wochen-Bereich:
$7.32
$8.2999
52-Wochen-Spanne:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Vergleichen Sie ZVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
7.94 | 427.54M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com South Africa
Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com
Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa
Zevra Therapeutics stock target raised to $18 at JMP By Investing.com - Investing.com South Africa
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts - Defense World
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Plans - GuruFocus.com
Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating - TipRanks
Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Zevra Therapeutics: Q4 Earnings Snapshot - mySA
ZEVRA THERAPEUTICS Earnings Results: $ZVRA Reports Quarterly Earnings - Nasdaq
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses - Investing.com
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses By Investing.com - Investing.com UK
Zevra Therapeutics: Q4 Earnings Snapshot -March 11, 2025 at 05:23 pm EDT - Marketscreener.com
Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours - Marketscreener.com
Zevra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewswire
Zevra Earnings: Q4 Revenue Surges to $12M as MIPLYFFA Launch Gains Traction - StockTitan
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects - Simply Wall St
Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Tuesday - Defense World
Rhumbline Advisers Has $568,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra at TD Cowen Conference: Strategic Shifts in Rare Disease Focus - Investing.com
(ZVRA) Long Term Investment Analysis - Stock Traders Daily
Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain - Yahoo Finance
Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - The Globe and Mail
Watkins Represents Zevra Therapeutics in Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher - Latham & Watkins LLP
Zevra Seals PRV Sale And Banks $150m - Citeline News & Insights
Zevra Therapeutics: Strategic Growth and Financial Strength Drive Buy Rating - TipRanks
Zevra Launches New Disease State Awareness Campaign, ‘Learn - GlobeNewswire
Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - The Manila Times
Zevra sells priority review voucher for $150m to support drug launches - Pharmaceutical Technology
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M - MedCity News
Zevra Therapeutics rises on agreement to sell its FDA priority review voucher for $150 mln - TradingView
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewswire
BRIEF—Zevra sells Miplyffa-linked PRV for $150 million - The Pharma Letter
Zevra Therapeutics to Sell Priority Review Voucher for $150 Million -February 27, 2025 at 11:12 am EST - Marketscreener.com
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million - MarketWatch
Zevra Therapeutics Sells Priority Review Voucher for $150M - TipRanks
Zevra Therapeutics stock rises on $150M asset sale By Investing.com - Investing.com Canada
Zevra Therapeutics stock rises on $150M asset sale - Investing.com
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - Benzinga
How Will Zevra Use Its Massive $150M Windfall? Non-Dilutive Funding Fuels Rare Disease Strategy - StockTitan
ZEVRA THERAPEUTICS Earnings Preview: Recent $ZVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results - The Manila Times
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zevra Therapeutics Inc-Aktie (ZVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schafer Joshua | CCO & EVP, Bus. Development |
Feb 13 '25 |
Sale |
7.86 |
10,500 |
82,527 |
29,486 |
| Clifton R. LaDuane | CFO & Treasurer |
Feb 13 '25 |
Sale |
7.86 |
11,000 |
86,471 |
51,361 |
| McFarlane Neil F. | President and CEO |
Feb 13 '25 |
Sale |
7.86 |
61,273 |
481,428 |
222,060 |
| McFarlane Neil F. | President and CEO |
Feb 14 '25 |
Sale |
8.05 |
30,544 |
245,962 |
191,516 |
0.49%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):